Omapatrilat Reduces Atherosclerosis in Mice
Author Information
Author(s): Zohar Levy, Ayana Dvir, Aviv Shaish, Svetlana Trestman, Hofit Cohen, Hana Levkovietz, Rita Rhachmani, Mordchai Ravid, Dror Harats
Primary Institution: Meir Hospital and Sheba Medical Center
Hypothesis
Does omapatrilat attenuate atherogenesis in diabetic and nondiabetic LDL receptor-deficient mice?
Conclusion
Omapatrilat treatment significantly reduces atherosclerotic plaque area in both diabetic and nondiabetic mice despite increasing plasma lipid levels.
Supporting Evidence
- Omapatrilat treatment resulted in a significant reduction of atherosclerotic plaque area in both diabetic and nondiabetic mice.
- The mean plaque area in omapatrilat-treated diabetic mice was significantly smaller than in nontreated controls.
- Omapatrilat treatment increased plasma cholesterol levels in both diabetic and nondiabetic mice.
- Diabetes induction resulted in significantly higher plasma glucose levels compared to nontreated animals.
- Omapatrilat did not affect weight gain in either diabetic or nondiabetic mice.
Takeaway
Omapatrilat helps keep the arteries healthy in mice, even if it raises some fat levels in the blood.
Methodology
LDL receptor-deficient mice were divided into groups, diabetes was induced in some, and omapatrilat was administered to evaluate its effects on atherosclerosis.
Limitations
The study was conducted on mice, which may not fully represent human responses.
Participant Demographics
Male LDL receptor-deficient mice, some diabetic and some nondiabetic.
Statistical Information
P-Value
P = .001 for diabetic mice; P = .002 for nondiabetic mice
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website